Abasaglar® (insulin glargin): Användning hos äldre

Detailed information

In elderly patients, 65 years of age or older, progressive deterioration of renal function may lead to a steady decrease in insulin requirements.^1-3

Caution should be exercised when Abasaglar is administered to elderly patients.⁴

In elderly patients with DM, the warning symptoms of hypoglycemia may be altered due to impaired counterregulatory hormonal responses. Elderly patients may be more prone to severe hypoglycemia due to a disconnect between the onset of hypoglycemic symptoms and cognitive dysfunction.²

Abasaglar Phase 3 Studies

In the Abasaglar phase 3 studies in patients with T1DM or T2DM, the safety outcomes that were evaluated for possible subgroup differences in response to study drug included the

• TEAEs, overall incidence and preferred terms with >5% incidence (nasopharyngitis and upper respiratory tract infection)

• overall incidence of allergic events from the special topic assessment

• overall incidence of injection site reactions

• overall incidence of SAEs, and

• incidence of TEAR.⁴

There were no significant treatment-by-entry age interactions for any of the safety outcomes analyzed, indicating no significant differential treatment effects on the safety outcomes across age categories.⁴

The safety analyses were not performed in patients ≥75 years of age as there were too few of these patients with events of

• upper respiratory tract infection

• allergic events

• injection site reactions

• SAEs, or

• TEAR.⁴

References

1. Abasaglar [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

2. Ligthelm RJ, Kaiser M, Vora J, Yale JF. Insulin use in elderly adults: risk of hypoglycemia and strategies for care. J Am Geriatr Soc. 2012;60(8):1564-1570. http://dx.doi.org/10.1111/j.1532-5415.2012.04055.x

3. Kulozik F, Hasslacher C. Insulin requirements in patients with diabetes and declining kidney function: differences between insulin analogues and human insulin? Ther Adv Endocrinol Metab. 2013;4(4):113-121. http://dx.doi.org/10.1177/2042018813501188

4. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Glossary

Abasaglar = Abasaglar® (insulin glargine) 100 units/mL

DM = diabetes mellitus

SAE = serious adverse event

T1DM = type 1 diabetes mellitus

T2DM = type 2 diabetes mellitus

TEAE = treatment-emergent adverse event

TEAR = treatment-emergent antibody response